Akeso and Dawnrays Biotechnology’s Ebronucimab (PCSK9 mAb) Reports Early Completion of Patient Enrollment in P-III Trial for Primary Hypercholesterolemia and Mixed Hyperlipidemia
Shots:
- Ebronucimab demonstrated a similar safety profile vs. the marketed PCSK9 mAb drugs with the same target, with drug-related AEs >5% and higher than PBO which only included the injection-site adverse reactions
- The results showed that Ebronucimab (450 mg, Q4W) can reduce LDL-C by 65.48% from baseline & 65.69% from the PBO arm; and 150 mg, Q2W can reduce LDL-C by 63.69% from baseline & 63.90% from the PBO arm
- Additionally, the company expects that Ebronucimab will be approved for marketing soon, which will provide a better choice for huge no. of cardiovascular patients in China
Ref: PR Newswire | Image: Akeso
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
